MICHAEL FRAZIER: Open Payments
NPI 1225396591 · WESTMINSTER, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,506 in 267 payments from 20 companies in 2025. Trend: 2023 $17 · 2024 $1,875 · 2025 $5,506
Food & beverage: $5,506
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 48 | $800 |
| Neurocrine BioSciences, Inc. | 27 | $677 |
| Teva Pharmaceuticals USA, Inc. | 37 | $609 |
| E.R. Squibb & Sons, L.L.C. | 17 | $554 |
| Alkermes, Inc. | 25 | $531 |
| ABBVIE INC. | 30 | $517 |
| Vanda Pharmaceuticals Inc. | 14 | $333 |
| Lundbeck LLC | 15 | $323 |
| Janssen Pharmaceuticals, Inc | 12 | $285 |
| Axsome Therapeutics, Inc. | 10 | $195 |
Products named: CAPLYTA, INGREZZA, COBENFY, ARISTADA, VRAYLAR, REXULTI, FANAPT, AUSTEDO XR.
Industry payments across CA — which companies pay providers there.
